Pritelivir mesylate is under clinical development by AiCuris Anti-infective Cures and currently in Phase III for Simplexvirus (HSV) Infections. According to GlobalData, Phase III drugs for ...

The FDA set August 29, 2025, as the PDUFA date for the 3-month leuprolide mesylate formulation, supported by phase 3 trial data. The FDA issued a Day-74 letter setting August 29, 2025, as the ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate ...

The FDA has accepted an NDA for a 3-month leuprolide mesylate formulation, with a PDUFA date set for August 29, 2025. A phase 3 trial showed 97.9% of patients achieved testosterone suppression to ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Doxazosin remains a commonly used antihypertensive medication, although its use has been tainted by recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack ...

Inhibikase Therapeutics, Inc.’s IKT share price has surged by 18.23%, which has investors questioning if this is right time ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.